Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

The US Food and Drug Administration (FDA) has granted clearance to CureVac's investigational new drug application (IND) for ...

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The addition of pembrolizumab to chemoradiotherapy improved PFS and OS for women with high-risk, locally advanced cervical cancer. The safety profile appeared consistent with that of the ...